Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000917520-26-000058
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Other non-current liabilities | 1,205 | 2,544 |
| Net cash provided by (used in) operating activities | 32,605 | (2,338) |
| INVESTING ACTIVITIES: | ||
| Purchases of property and equipment | (27,155) | (49,066) |
| Purchases of short-term investments | (30,976) | (8,502) |
| Net cash used in investing activities | (58,131) | (57,568) |
| FINANCING ACTIVITIES: | ||
| Proceeds from borrowings of long-term indebtedness | 75,900 | 67,300 |
Item 1. Financial Statements
FAQ
- What is Integra LifeSciences's capex?
- Integra LifeSciences (IART) reported capex of $12.31M in Q2 2026.
- How has Integra LifeSciences's capex changed year-over-year?
- Integra LifeSciences's capex decreased by 38.9% year-over-year, from $20.15M to $12.31M.
- What is the long-term trend for Integra LifeSciences's capex?
- Over 4 years (2021 to 2025), Integra LifeSciences's capex has grown at a 14.1% compound annual growth rate (CAGR), from $48.02M to $81.44M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Integra LifeSciences's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude